Page last updated: 2024-11-04

vorinostat and Leishmania Infection

vorinostat has been researched along with Leishmania Infection in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Patil, V1
Guerrant, W1
Chen, PC1
Gryder, B1
Benicewicz, DB1
Khan, SI1
Tekwani, BL1
Oyelere, AK1

Other Studies

1 other study available for vorinostat and Leishmania Infection

ArticleYear
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
    Bioorganic & medicinal chemistry, 2010, Jan-01, Volume: 18, Issue:1

    Topics: Antimalarials; Antiprotozoal Agents; Histone Deacetylase Inhibitors; Histone Deacetylases; Leishmani

2010
chemdatabank.com